COMBI 40+ ABI Auditory Brainstem Implant - Med-El
COMBI 40+ ABI Auditory Brainstem Implant - Med-El
COMBI 40+ ABI Auditory Brainstem Implant - Med-El
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />
<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong>
2<br />
<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />
<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong><br />
The <strong>COMBI</strong> <strong>40+</strong> <strong>Auditory</strong> <strong>Brainstem</strong><br />
<strong>Implant</strong> (<strong>ABI</strong>) is a highly advanced<br />
technological system for individuals<br />
with hearing loss due to a<br />
nonfunctional auditory nerve, such as<br />
in cases of Neurofibromatosis Type 2<br />
(NF2). Bypassing the inner ear and<br />
auditory nerve, the <strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />
allows high-rate stimulation of the<br />
cochlear nucleus (CN) and can<br />
provide recipients a variety<br />
of sound sensations.<br />
N e u ro f i b ro m a t o s i s<br />
Type 2 (NF2)<br />
Neurofibromatosis Type 2 (NF2), also known<br />
as Bilateral Acoustic NF (BAN), is a rare<br />
genetic disorder that affects approximately 1<br />
in 40,000 individuals. NF2 can either be<br />
inherited or occur spontaneously without any<br />
apparent familial history. The gene defect was<br />
isolated in 1993 to the merlin tumor<br />
suppressor area of chromosome 22. NF2 is<br />
characterized by non-malignant tumor growth,<br />
primarily in the brain and spinal cord. A<br />
hallmark of NF2 is the presence of bilateral<br />
acoustic neuromas, which originate in the<br />
vestibular nerve and often invade the adjacent<br />
auditory nerve, causing progressive hearing<br />
loss and ultimately deafness. <strong>Auditory</strong><br />
<strong>Brainstem</strong> <strong>Implant</strong>s stimulate the cochlear<br />
nucleus (CN) and have the potential to<br />
provide NF2 patients hearing sensations that<br />
assist with sound awareness and<br />
communication.<br />
• implant housing<br />
containing implant circuitry<br />
and a powerful microchip<br />
• active electrode array<br />
placed on the cochlear nucleus<br />
during implantation
<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong> Features<br />
• 12 contacts<br />
arranged on a soft, pre-shaped silicone paddle<br />
• Reliable, robust ceramic case,<br />
similar in hardness to the surrounding bone<br />
• MRI safe with no additional surgery necessary<br />
• Comprehensive telemetry<br />
• High-performance CIS+ speech coding<br />
with infinitely variable stimulation rates<br />
• Safety features<br />
output capacitors, telemetry, self-check integrity, etc.<br />
• Compatible with the TEMPO+ BTE<br />
speech processor including five wearing options<br />
3
4<br />
Special <strong>Implant</strong>s for Special Cases<br />
At MED-EL, we strive to continually offer the safest and most advanced implants<br />
for the treatment of severe hearing impairment. MED-EL offers a variety of<br />
cochlear implants, with options for special cases.<br />
<strong>COMBI</strong> <strong>40+</strong><br />
Standard <strong>El</strong>ectrode Array<br />
24 contacts arranged as connected pairs for<br />
12-channel high-rate stimulation. Deep<br />
electrode insertion for stimulation of the<br />
complete frequency range.<br />
<strong>COMBI</strong> <strong>40+</strong><br />
Compressed <strong>El</strong>ectrode Array<br />
(C<strong>40+</strong>S)<br />
For partial ossification or malformation of the<br />
cochlea.<br />
<strong>COMBI</strong> <strong>40+</strong><br />
Split <strong>El</strong>ectrode Array (C<strong>40+</strong> GB)<br />
For cases of complete cochlear ossification.<br />
Revolutionary technology: the <strong>COMBI</strong> <strong>40+</strong><br />
<strong>ABI</strong> (<strong>Auditory</strong> <strong>Brainstem</strong> <strong>Implant</strong>) provides<br />
Neurofibromatosis Type II patients hearing<br />
sensations for sound awareness and<br />
communication.<br />
Special Solutions<br />
MED-EL is committed to working<br />
with Cochlear <strong>Implant</strong> professionals<br />
to provide implant solutions for<br />
unique anatomical situations. Please<br />
contact your nearest MED-EL office<br />
for more information.
Benefits of the <strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />
Individuals vary in the amount of benefit they receive from the <strong>COMBI</strong> <strong>40+</strong><br />
<strong>ABI</strong>. While performance generally does not approach the levels common<br />
among recipients of cochlear implants,<br />
the <strong>ABI</strong> provides a variety of hearing sensations that are helpful for speech<br />
understanding and lip reading as well as environmental sound detection. For<br />
optimal performance, <strong>ABI</strong> candidates should understand the limitations of the<br />
implant and be committed to<br />
long-term rehabilitation and regular programming.<br />
<strong>COMBI</strong> <strong>40+</strong> <strong>ABI</strong><br />
recipients report<br />
benefits in:<br />
• detecting everyday<br />
environmental sounds<br />
• face-to-face<br />
communication<br />
• greater confidence in<br />
social situations<br />
5
21060<br />
WORLDWIDE LEADER IN HEARING IMPLANTS<br />
MED-EL Worldwide Headquarters<br />
Fürstenweg 77a, A-6020 Innsbruck, Austria<br />
Tel.: +43-512-28 88 89<br />
Fax: +43-512-29 33 81<br />
office@medel.com<br />
MED-EL GmbH Niederlassung Wien<br />
office@at.medel.com<br />
MED-EL Deutschland GmbH<br />
office@medel.de<br />
MED-EL Deutschland GmbH Büro Berlin<br />
office-berlin@medel.de<br />
MED-EL Unità Locale Italiana<br />
ufficio.italia@medel.com<br />
VIBRANT MED-EL<br />
Hearing Technology France<br />
office@fr.medel.com<br />
MED-EL GmbH Sucursal España<br />
office@es.medel.com<br />
MED-EL GmbH Sucursal em Portugal<br />
office@pt.medel.com<br />
MED-EL UK Ltd<br />
office@uk.medel.com<br />
MED-EL Corporation<br />
(North America)<br />
implants@medelus.com<br />
MED-EL Latino America S.R.L.<br />
medel@medel.com.ar<br />
MED-EL Middle East FZE<br />
medeluae@emirates.net.ae<br />
MED-EL India Private Ltd<br />
implants@medel.in<br />
MED-EL China Office<br />
office@medel.net.cn<br />
MED-EL Singapore Regional<br />
Service Office<br />
office@sg.medel.com<br />
MED-EL Philippines<br />
Regional Headquarters<br />
office@ph.medel.com<br />
MED-EL Hong Kong Office<br />
office@hk.medel.com<br />
MED-EL Japan Co., Ltd<br />
info@medel.co.jp<br />
www.medel.com